Infant Bacterial Therapeutics AB (publ)

OM:IBT B Stock Report

Market Cap: SEK 514.6m

Infant Bacterial Therapeutics Valuation

Is IBT B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IBT B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IBT B's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IBT B's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IBT B?

Key metric: As IBT B barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IBT B. This is calculated by dividing IBT B's market cap by their current book value.
What is IBT B's PB Ratio?
PB Ratio2.5x
BookSEK 204.03m
Market CapSEK 514.61m

Price to Book Ratio vs Peers

How does IBT B's PB Ratio compare to its peers?

The above table shows the PB ratio for IBT B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average11.5x
NEWBRY Newbury Pharmaceuticals
1.6x130.0%SEK 80.5m
DICOT Dicot Pharma
32.5xn/aSEK 406.5m
ENZY Enzymatica
2x67.8%SEK 388.4m
ANNX Annexin Pharmaceuticals
10x113.9%SEK 250.5m
IBT B Infant Bacterial Therapeutics
2.5xn/aSEK 514.6m

Price-To-Book vs Peers: IBT B is good value based on its Price-To-Book Ratio (2.5x) compared to the peer average (11.5x).

Price to Book Ratio vs Industry

How does IBT B's PB Ratio compare vs other companies in the SE Pharmaceuticals Industry?

5 CompaniesPrice / BookEstimated GrowthMarket Cap
KDEV Karolinska Development
0.2x5.8%US$25.46m
EEVIA Eevia Health Oyj
0.5xn/aUS$1.30m
PHARM Pharmiva
0.6xn/aUS$931.42k
REDW Redwood Pharma
0.3xn/aUS$301.09k
IBT B 2.5xIndustry Avg. 2.9xNo. of Companies7PB03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IBT B is good value based on its Price-To-Book Ratio (2.5x) compared to the Swedish Pharmaceuticals industry average (3.1x).

Price to Book Ratio vs Fair Ratio

What is IBT B's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IBT B PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IBT B's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£162.4b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,462.00

7D

5.0%

1Y

8.2%

Swedish Orphan Biovitrum

SEK 99.6b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.00

7D

-2.7%

1Y

14.5%

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

7D

-8.1%

1Y

n/a